Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 7/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21130547 | 0.95 | HDAC3 (0.40) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL23863507 | 0.82 | HDAC3 (0.41) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1130229 | 0.79 | PKM (0.46) | ADORA2BMAPTVEGFAEGLN1CNR1 | |
| SCHEMBL12859678 | 0.79 | PARP1 (0.40) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL21595152 | 0.77 | HDAC3 (0.39) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL608253 | 0.77 | CNR2 (0.43) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1129274 | 0.76 | ADORA2B (0.35) | HDAC1HDAC6ADORA2BMAPTMEN1 | |
| SCHEMBL1129892 | 0.76 | DRD2 (0.44) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1997416 | 0.76 | MAPT (0.50) | ADORA2BMAPTMEN1HTTKMT2A | |
| SCHEMBL23531483 | 0.76 | KDM4E (0.38) | ADORA2BMAPK1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163927-B2 | Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-04-24 | — | — | US | disclosed |
| US-8163927-B2 | Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-04-24 | — | — | US | disclosed |
| US-8163927-B2 | Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2012-04-24 | — | — | US | disclosed |
| EP-2010518-B1 | AZABICYCLO [3. 1. O] HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LTD (GB) | 2011-02-16 | — | — | EP | disclosed |
| EP-2010518-B1 | AZABICYCLO [3. 1. O] HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LTD (GB) | 2011-02-16 | — | — | EP | disclosed |
| US-20100063097-A1 | Azabicyclo [3.1.0] Hexane Derivatives as Modulators of Dopamine D3 Receptors | GLAXO GROUP LIMITED | 2010-03-11 | — | — | US | disclosed |
| US-20100063097-A1 | Azabicyclo [3.1.0] Hexane Derivatives as Modulators of Dopamine D3 Receptors | GLAXO GROUP LIMITED | 2010-03-11 | — | — | US | disclosed |
| US-20100063097-A1 | Azabicyclo [3.1.0] Hexane Derivatives as Modulators of Dopamine D3 Receptors | GLAXO GROUP LIMITED | 2010-03-11 | — | — | US | disclosed |
| EP-2010518-A1 | AZABICYCLO [3. 1. O] HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007113258-A1 | AZABICYCLO [3. 1. O] HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113258-A1 | AZABICYCLO [3. 1. O] HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063097-A1 | Azabicyclo [3.1.0] Hexane Derivatives as Modulators of Dopamine D3 Receptors | DRD3, DRD2, DRD1 | HDAC3 254/4885HDAC4 1317/4885HDAC1 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.